显著降低酒精使用障碍症状的体重减轻的二次性塞马格卢提德治疗:一个案例系列
Jesse R Richards1,2, Madisen Fae Dorand1, Kyleigh Royal3
1Department of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa.
The Journal of clinical psychiatry
|November 29, 2023
概括
作为一种类似葡萄糖类-1受体激动剂 (GLP-1RA) 的赛马格卢提德,在一系列小病例中显著减少了酒精使用障碍 (AUD) 的症状. 这表明GLP-1RAs可能为AUD治疗提供新的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 酒精使用障碍 (AUD) 是全球可预防死亡的主要原因之一.
- 目前FDA批准的AUD药物治疗方法有限.
- 类似葡萄糖类-1受体激动剂 (GLP-1RAs) 显示出降低酒精消费的临床前前景.
研究的目的:
- 研究为减肥而接受塞马格卢提德治疗的患者对AUD症状的作用.
- 评估塞马格卢提德的使用是否与AUD症状的下降有关.
主要方法:
- 对患者的回顾性图表审查,这些患者在减肥治疗中使用了塞马格卢提德.
- 纳入标准:在开始服用西马格卢提德前进行过阳性酒精使用障碍鉴定测试 (AUDIT) 查.
- 配对t测试用于比较治疗前和治疗后的AUDIT分数.
主要成果:
- 所有6名确定的患者 (100%) 均显示AUD症状有显著改善.
- 在AUDIT得分的平均降低为9.5分 (P<.001).
结论:
- 这一案例系列支持了关于AUD治疗GLP-1RAs的临床前发现.
- 塞马格卢提德在减少AUD症状方面表现出潜在的有效性.
- 需要进一步的随机化,安慰剂对照试验来证实这些发现.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
182
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
182
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Drugs for Treatment of Diarrhea-Predominant IBS
182
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
182
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
CNS Depressants: Alcohol and Nicotine
215
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
215
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190


